Shenzhen Hepalink Pharmaceutical Group Valuation

Q: What is the Fair Price of SHEZ.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SHEZ.F ($0.47) is trading below our estimate of [[fair value]] ($8.58)

Is SHEZ.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SHEZ.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SHEZ.F ($0.47) is trading below our estimate of fair value ($8.58)

Significantly Below Fair Value: SHEZ.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SHEZ.F?

Key metric: As SHEZ.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SHEZ.F. This is calculated by dividing SHEZ.F's market cap by their current revenue.
What is SHEZ.F's PS Ratio?
PS Ratio	2.9x
Sales	CN¥5.57b
Market Cap	CN¥14.53b

SHEZ.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3x
Enterprise Value/EBITDA	58.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does SHEZ.F's PS Ratio compare to its peers?

The above table shows the PS ratio for SHEZ.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5x
SUPN Supernus Pharmaceuticals	3.1x	5.9%	US$2.0b
NDOI Endo	1x	n/a	US$1.9b
LGND Ligand Pharmaceuticals	15x	15.0%	US$2.3b
AMRX Amneal Pharmaceuticals	1x	5.6%	US$2.6b
SHEZ.F Shenzhen Hepalink Pharmaceutical Group	2.9x	5.0%	US$14.5b

Price-To-Sales vs Peers: SHEZ.F is good value based on its Price-To-Sales Ratio (2.9x) compared to the peer average (5.3x).

Price to Sales Ratio vs Industry

How does SHEZ.F's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

71 Companies	Price / Sales	Estimated Growth	Market Cap
OGN Organon	0.6x	-0.06%	US$3.94b
PRGO Perrigo	0.9x	3.4%	US$3.83b
BHC Bausch Health Companies	0.3x	1.5%	US$2.93b
AMRX Amneal Pharmaceuticals	1x	5.6%	US$2.60b

71 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: SHEZ.F is expensive based on its Price-To-Sales Ratio (2.9x) compared to the US Pharmaceuticals industry average (2.8x).

Price to Sales Ratio vs Fair Ratio

What is SHEZ.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SHEZ.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SHEZ.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.69

1.2%

68.9%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

6.8%

-3.2%